Stifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) Eli Lilly's Solanezumab did not meet its primary endpoint in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE